The Clinical Carbetocin Myocardium Trial

• Status: Completed
• Trial end date: 2019-01-28
• Target enrollment: 0
• Participant gender: Female

Summary

Randomized comparison of different cardiotoxicity of carbetocin and oxytocin.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oslo University Hospital
• Treatments: Carbetocin; Oxytocin

Criteria

Inclusion Criteria:

1. Healthy pregnant women age 18 to 50

2. Singleton pregnancy at gestational age 36 weeks or more

3. Able to read and understand Norwegian.

Exclusion Criteria:

1. Patients with placenta pathology such as praevia, acreta, pre-eclampsia

2. Patients with bleeding disorders including vonWillebrand disease type I.

3. Known intolerance to one of the two drugs.

4. Patients with prolonged QT-time or other serious cardiac diseases.

5. Liver or kidney failure.

6. Epilepsy.

7. Any medical reason why, in the opinion of the investigator, the patient should not participate